ALEXANDRIA, Egypt–(BUSINESS WIRE)–Pharco Pharmaceuticals, Inc. announced today that Gamal Esmat, M.D.,
Professor of Haepatology and Endemic Medicine at Cairo University and
WHO viral hepatitis expert, will present advanced results of the
abstract entitled: High Virologic Response Rate in Egyptian
HCV-Genotype 4 Patients Treated with Ravidasvir (PPI-668) and
Sofosbuvir: Results of a Large Multicenter Phase 3 Registrational Trial.
The late-breaker, oral presentation will take place on Monday, November
16, 2015 at the Moscone West Convention Center in San Francisco, CA at
Pharco Pharmaceuticals, Inc. is the largest manufacturer of
pharmaceuticals in Egypt, focused on research, formulation,
manufacturing and commercialisation of pharmaceutical products in the
MENA region. Today Pharco employs over 8,000 employees, and has over
500M product sales units—ranking as the leader in the Egyptian
pharmaceutical market. Pharco also exports to 47 countries around the
world. Pharco works towards one goal…to provide highly effective
and safe pharmaceutical products to patients at an affordable price.
Pharco licensed ravidasvir hydrochloride (formerly known as PPI-668)
from Presidio Pharmaceuticals, a San Francisco-based clinical stage,
specialty pharmaceutical company.
For more information, please visit our website at: www.pharco.org
Presidio Pharmaceuticals, Inc. is a San Francisco-based clinical-stage
pharmaceutical company dedicated to the discovery and development of
small-molecule antiviral therapeutics. Presidio’s current focus is on
effective therapies for HCV infection, and includes pan-genotypic
inhibitors of NS5A (ravidasvir) and NS5B (PPI-383).
For more information on ravidasvir, please visit www.presidiopharma.com
EEPI – Pharco Corporation
Leo J. Redmond, 415-655-7560
Chief Financial Officer &